SPORTS MEDICINE

WEREWOLF◊ FLOW 50◊ COBLATION◊ Wand

Control the flow for optimal resection performance across multiple types of soft tissue.
Part of our 10-year dedication to continuous improvement and impact in sports medicine.

Hero 1_COBLATION_FLOW_50_Wand_791101.png

COBLATION Wand with FLOW~IQ◊ Technology

Uses WEREWOLF COBLATION Technology, designed to take speed and precision to a new level*1-3 for faster patient recovery*4 and better patient outcomes.**4-6 Safe for use on multiple joint soft tissues,7-11 with FLOW~IQ Technology helping to provide automated outflow control to deliver a new standard of ablation performance.

Use of COBLATION Wands has been shown to result in better economic outcomes.***12-15

Hero 2_COB18_Flow50_Tip_Top_14294.png


Product Features

10 years of FLOW Wands​

The origin of FLOW Wands was inspired by a simple but important need: to allow surgeons more control and access across different joint indications and tissue types when using COBLATION Technology. ​

Adapting to growing needs and expectations in arthroscopic surgery, painstaking research and development was dedicated to refine both our wand design and performance. ​​

Introducing distinct improvements in our wand geometry, electrode design and outflow control, the FLOW 50◊ Wand and FLOW 90◊ Wand harnessed FLOW~IQ◊ Technology to enhance the standard of ablation across multiple joint soft tissues. ​​

FLOW Wands represent the tactile expression of COBLATION technology’s core promise of control and performance…and there’s more to come.​

COB18_WEREWOLF_Controller_Flow90_Flow50_3QtrLeft_14207.png


Reference Materials

Medical education



Related Products



Disclaimer

*As compared to our predicate wand. Demonstrated in vitro.

**As compared to mechanical debridement for knee chondroplasty; n=60.

***In Germany, Spain, United Kingdom and United States, compared to mechanical debridement for knee chondroplasty.

****As demonstrated ex vivo in a single cartilage and meniscus sample.

*****Demonstrated in vitro. Compared to the AMBIENT◊ SUPER MULTIVAC◊ 50.

******Minimal damage (100-200μm) evident in untargeted cartilage tissue, as demonstrated ex vivo. Cell damage may vary depending on protocol use.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product’s applicable Instructions for Use (IFU) prior to use.

Citations
  1. ArthroCare 2014. Internal report. P/N 53303-01_A.
  2. ArthroCare 2014. Internal report. P/N 54952-01_A.
  3. ArthroCare 2014. Internal report. P/N 52918-01.
  4. Spahn G, et al. Knee Surg Sports Traumatol Arthrosc. 2008;16(6):565-573.
  5. Spahn G, et al. Knee Surg Sports Traumatol Arthrosc. 2016;24(5):1560-1568.
  6. Spahn G, et al. Arthroscopy. 2010;26(9 Suppl):S73-80.
  7. Chivot M, et al. Eur J Orthop Surg Traumatol, 2019;29(6):1205-1210.
  8. Gharaibeh M, et al. Cartilage. 2018;9(3):241-247.
  9. Liu YJ, et al. Clin Orthop Relat Res. 2009;467(3):799-804.
  10. Sean NY, et al. Foot Ankle Surg. 2010;16(4):174-177.
  11. Taverna E, et al. Arthroscopy. 2007;23(10):1042-1051.
  12. Adeyami A, et al. Value in Health. 2018;21:S168.
  13. Adeyami A, et al. International Conference on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; May 25-26, 2017; London, UK.
  14. Adeyemi A, et al. Value in Health. 2017;20:A584.
  15. Adeyami A, et al. ISPOR 20th Annual European Congress; 4-8 Nov, 2017; Glasgow, Scotland, UK.
  16. ArthroCare 2014. Internal report. P/N 48261_01_A.
  17. ArthroCare 2017. Internal report. P/N 92306_01_A.
  18. ArthroCare 2015. Internal report. P/N 65200_01_A.
  19. ArthroCare 2014. Internal report. P/N 54950_01_A.
  20. Amiel, D et al. Arthroscopy, 2004;20(5):503-510.

Title

Text

Explore